{"filing":{"accession_number":"0001193125-26-326119","cik":"0001674930","ticker":"FLGT","company_name":"Fulgent Genetics, Inc.","form":"8-K","filing_date":"2026-07-30","report_date":"2026-07-30","primary_document":"flgt-20260730.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1674930/000119312526326119/flgt-20260730.htm"},"events":[{"id":22607,"run_id":20453,"accession_number":"0001193125-26-326119","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.97,"summary":"Fulgent Genetics issued a press release on July 30, 2026 announcing Q2 2026 financial results, disclosing revenue of $85.4 million (20.1% sequential growth), a GAAP loss of $29.5 million, and revised full-year 2026 revenue guidance of $330.0–$340.0 million.","company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","filing_date":"2026-07-30","form":"8-K","submitted_at":null,"items":[{"id":22594,"accession_number":"0001193125-26-326119","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Fulgent Genetics issued a press release on July 30, 2026 announcing financial results for the fiscal quarter ended June 30, 2026, disclosing Q2 2026 revenue of $85.4 million (20.1% sequential growth), GAAP loss of $29.5 million, and revised full-year 2026 revenue guidance to $330.0–$340.0 million. This is a standard quarterly earnings release disclosure under Item 2.02, material to investors assessing the company's operational and financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T02:22:59.566051+00:00","company_name":"","ticker":null,"filing_date":""},{"id":22595,"accession_number":"0001193125-26-326119","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure furnishes an earnings release (Exhibit 99.1) announcing Fulgent's second quarter 2026 financial results, including revenue of $85.4 million (20.1% sequential growth), GAAP loss of $29.5 million, and revised full-year revenue guidance of $330.0–$340.0 million. The press release contains detailed financial metrics, management commentary, and forward-looking guidance, which are hallmarks of an earnings announcement. Although Item 7.01 is used for \"other events,\" the substance of the disclosure is a quarterly earnings release, which is material to investors assessing the company's financial performance and trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T02:22:59.566051+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22594,"accession_number":"0001193125-26-326119","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Fulgent Genetics issued a press release on July 30, 2026 announcing financial results for the fiscal quarter ended June 30, 2026, disclosing Q2 2026 revenue of $85.4 million (20.1% sequential growth), GAAP loss of $29.5 million, and revised full-year 2026 revenue guidance to $330.0–$340.0 million. This is a standard quarterly earnings release disclosure under Item 2.02, material to investors assessing the company's operational and financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T02:22:59.566051+00:00","company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","filing_date":"2026-07-30"},{"id":22595,"accession_number":"0001193125-26-326119","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure furnishes an earnings release (Exhibit 99.1) announcing Fulgent's second quarter 2026 financial results, including revenue of $85.4 million (20.1% sequential growth), GAAP loss of $29.5 million, and revised full-year revenue guidance of $330.0–$340.0 million. The press release contains detailed financial metrics, management commentary, and forward-looking guidance, which are hallmarks of an earnings announcement. Although Item 7.01 is used for \"other events,\" the substance of the disclosure is a quarterly earnings release, which is material to investors assessing the company's financial performance and trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-01T02:22:59.566051+00:00","company_name":"Fulgent Genetics, Inc.","ticker":"FLGT","filing_date":"2026-07-30"}]}